Genprex (GNPX) traded flat 0 % during a 24 hours period ending at 01:22 PM Central Europe on Tuesday 27th. One Genprex stock can currently be bought for about USD 1.81 on popular exchanges. Current supply of Genprex stocks is 817.7 k. Genprex has a current market capitalization of USD 1.5 mn and approximately USD 131.2 k worth of Genprex was traded on exchanges in the last 24 hours. Since last month end, Genprex has traded -35.59 % down. Simple moving average of last 200 days is at USD 21.5. The highest price of past 52 weeks was recorded at USD 158.18 on 10/29/2025. 52 weeks low was at USD 1.79 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Freight (FRGT) traded down -9.91 % and now trades at USD 1.01. Current market capitalisation for Freight is USD 1.7 mn.

  • Matinas Biopharma I (MTNB) traded down -2.41 % and now trades at USD 1.66. Matinas Biopharma I has a market capitalisation of USD 1.6 mn.

  • Onconetix (ONCO) traded down -4.55 % and now trades at USD 0.4. Current market capitalisation for Onconetix is USD 1.7 mn. Onconetix, Inc. announced that its Board has approved a one‑for‑ten reverse stock split of its common shares, slated to take effect on November 6, 2026 at 12:01 a.m. Eastern Time. The split will automatically combine every ten shares into one, reducing the outstanding share count while leaving the authorized shares and par value unchanged. Shareholders who would otherwise receive fractional shares will be paid in cash. The company’s trading symbol on the Nasdaq will remain ONCO, and a new CUSIP number will be assigned. The reverse split is part of a broader corporate action that maintains ownership percentages and the rights of shareholders. The company continues to focus on its oncology diagnostics portfolio, including the Proclarix® test, and has provided standard forward‑looking statements in its filing.

  • Curis (CRIS) traded down -2.56 % and now trades at USD 0.38. Curis has a market capitalisation of USD 1.6 mn.

About Genprex

Genprex, Inc. is a biotechnology company that specializes in discovering and developing immunogene therapies for cancer treatment. Additionally, they provide clinical research, gene therapies, consulting, and other related medical services, catering to customers in the United States. Their website is www.genprex.com , and they are listed on the Nasdaq stock exchange. Their Initial Public Offering (IPO) date was March 29, 2018.